Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Caniglia EC, et al. Among authors: barrufet p. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):102-109. doi: 10.1097/QAI.0000000000001562. J Acquir Immune Defic Syndr. 2018. PMID: 28991888 Free PMC article.
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L; ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team. Podzamczer D, et al. Among authors: barrufet p. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):139-47. doi: 10.1097/QAI.0b013e31802bf122. J Acquir Immune Defic Syndr. 2007. PMID: 17106274 Clinical Trial.
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team. Martínez E, et al. Among authors: barrufet p. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5. J Acquir Immune Defic Syndr. 2009. PMID: 19398921 Clinical Trial.
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group. Troya J, et al. Among authors: barrufet p. PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. PLoS One. 2016. PMID: 27727331 Free PMC article.
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.
Casadellà M, Santos JR, Noguera-Julian M, Micán-Rivera R, Domingo P, Antela A, Portilla J, Sanz J, Montero-Alonso M, Navarro J, Masiá M, Valcarce-Pardeiro N, Ocampo A, Pérez-Martínez L, Pasquau J, Vivancos MJ, Imaz A, Carmona-Oyaga P, Muñoz-Medina L, Villar-García J, Barrufet P, Paredes R; INSTINCT Study Group. Casadellà M, et al. Among authors: barrufet p. J Antimicrob Chemother. 2020 Dec 1;75(12):3517-3524. doi: 10.1093/jac/dkaa349. J Antimicrob Chemother. 2020. PMID: 32929472
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group. Pulido F, et al. Among authors: barrufet p. Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734. Clin Infect Dis. 2017. PMID: 29020293 Clinical Trial.
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
Santos JR, Casadellà M, Noguera-Julian M, Micán-Rivera R, Domingo P, Antela A, Portilla J, Sanz J, Montero-Alonso M, Navarro J, Masiá M, Valcarce-Pardeiro N, Ocampo A, Pérez-Martínez L, García-Vallecillos C, Vivancos MJ, Imaz A, Iribarren JA, Hernández-Quero J, Villar-García J, Barrufet P, Paredes R; INSTINCT study group. Santos JR, et al. Among authors: barrufet p. Front Cell Infect Microbiol. 2023 Jun 26;13:1187999. doi: 10.3389/fcimb.2023.1187999. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37434782 Free PMC article.
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM; PISCIS study group. Nomah DK, et al. Lancet HIV. 2021 Nov;8(11):e701-e710. doi: 10.1016/S2352-3018(21)00240-X. Epub 2021 Oct 13. Lancet HIV. 2021. PMID: 34655549 Free PMC article.
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti AJ, Dalmau D, Casabona J, Miró JM, Falcó V; PISCIS study group. Burgos J, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):108-116. doi: 10.1093/jac/dkac361. J Antimicrob Chemother. 2022. PMID: 36308326
70 results